Key clinical point: When compared with platinum-based chemotherapy, atezolizumab monotherapy can improve overall survival in treatment-naive patients with stage IV non–small cell lung cancer (NSCLC) and high PD-L1 expression.
Major finding: Among patients with PD-L1 expression of 50% or greater on tumor cells or 10% or greater on tumor-infiltrating immune cells, the median overall survival was 13.1 months with chemotherapy and 20.2 months with atezolizumab (hazard ratio, 0.59; P = .0106).
Study details: Phase 3 trial of 554 patients
Disclosures: The trial is sponsored by Hoffmann-La Roche, and Dr. Giaccone disclosed grants and nonfinancial support from the company.
Giaccone G et al. SITC 2019,.